- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07543731
A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab (VICTORION-LEAP)
July 14, 2026 updated by: Novartis Pharmaceuticals
Real-World Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab in Italy
This study aims to evaluate the long-term adherence and persistence to inclisiran and anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) in real-world clinical practice.
Study Overview
Status
Recruiting
Study Type
Observational
Enrollment (Estimated)
5995
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Novartis Pharmaceuticals
- Phone Number: +41613241111
- Email: novartis.email@novartis.com
Study Contact Backup
- Name: Novartis Pharmaceuticals
Study Locations
-
-
-
Basel, Switzerland, CH-4056
- Recruiting
- Novartis
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Adult patients in Italy who initiated inclisiran, evolocumab, or alirocumab treatment during the identification period with at least 18 months of follow-up.
Description
Inclusion criteria:
- A first ever prescription of injection of inclisiran, evolocumab, or alirocumab during the identification period.
- Age ≥18 years at index date.
- With at least 12 months data availability prior to index date.
Exclusion criteria:
• Patients who received either evolocumab or alirocumab as their index study drug and who were dispensed the other anti-PCSK9-mAb (alirocumab and evolocumab respectively) before the identification period.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Inclisiran Cohort
Patients receiving inclisiran injection(s).
|
|
Evolocumab Cohort
Patients receiving evolocumab injection(s).
|
|
Alirocumab Cohort
Patients receiving alirocumab injection(s).
|
|
Pooled Anti-PCSK9-mAb Cohort
Patients receiving anti-PCSK9-mAbs either evolocumab or alirocumab.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of Days Covered (PDC) With Inclisiran
Time Frame: 6 months after index date and every 3 months thereafter until the end of follow-up, assessed up to 48 months
|
PDC is defined as the number of days with medication supply (covered days) within a period of interest divided by the number of days in the period of interest.
Index date is the date of first use of the treatment.
|
6 months after index date and every 3 months thereafter until the end of follow-up, assessed up to 48 months
|
|
Annual PDC With Inclisiran
Time Frame: 0-12 months, 12-24 months, 24-48 months
|
PDC is defined as the number of days with medication supply (covered days) within a period of interest divided by the number of days in the period of interest.
|
0-12 months, 12-24 months, 24-48 months
|
|
Persistence With Inclisiran Treatment
Time Frame: 6 months after index date and every 3 months thereafter until the end of follow-up, assessed up to 48 months
|
Persistence is defined as time to discontinuation by exceeding a pre-specified allowable gap beyond the scheduled time for the next dose/prescription.
Index date is the date of first use of the treatment.
|
6 months after index date and every 3 months thereafter until the end of follow-up, assessed up to 48 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PDC With Anti-PCSK9-mAbs
Time Frame: 6 months after index date and every 3 months thereafter until the end of follow-up, assessed up to 48 months
|
PDC is defined as the number of days with medication supply (covered days) within a period of interest divided by the number of days in the period of interest.
Index date is the date of first use of the treatment.
|
6 months after index date and every 3 months thereafter until the end of follow-up, assessed up to 48 months
|
|
Annual PDC With Anti-PCSK9-mAbs
Time Frame: 0-12 months, 12-24 months, 24-48 months
|
PDC is defined as the number of days with medication supply (covered days) within a period of interest divided by the number of days in the period of interest.
|
0-12 months, 12-24 months, 24-48 months
|
|
Persistence With Anti-PCSK9-mAb Treatment
Time Frame: 6 months after index date and every 3 months thereafter until the end of follow-up, assessed up to 48 months
|
Persistence is defined as time to discontinuation by exceeding a pre-specified allowable gap beyond the scheduled time for the next dose/prescription.
Index date is the date of first use of the treatment.
|
6 months after index date and every 3 months thereafter until the end of follow-up, assessed up to 48 months
|
|
Baseline Demographics
Time Frame: Baseline
|
Baseline
|
|
|
Baseline Clinical Characteristics: Number of Patients by Diagnosis
Time Frame: Baseline
|
Diagnoses include primary hypercholesterolemia, mixed dyslipidemia, homozygous familial hypercholesterolemia, and atherosclerotic cardiovascular disease (ASCVD) where available.
|
Baseline
|
|
Baseline Clinical Characteristics: Number of Patients by Comorbidity
Time Frame: Baseline
|
Baseline
|
|
|
Baseline Clinical Characteristics: Charlson Comorbidity Index (CCI) Score
Time Frame: Baseline
|
CCI is a weighted index that takes into account both the number and the seriousness of comorbid diseases.
It predicts the ten-year mortality for a patient who may have a range of comorbid conditions.
CCI can be categorized as low (0-1) and high (≥2).
|
Baseline
|
|
PDC With Lipid Lowering Therapies (LLTs) at Baseline
Time Frame: Baseline
|
PDC is defined as the number of days with medication supply (covered days) within a period of interest divided by the number of days in the period of interest.
|
Baseline
|
|
Number of Patients by LLTs Received
Time Frame: Every 3 months from baseline through index date until the end of follow-up, assessed up to 48 months
|
Treatment patterns of LLT use.
Index date is the date of first use of the treatment.
|
Every 3 months from baseline through index date until the end of follow-up, assessed up to 48 months
|
|
Number and Percentage of Patients Receiving Each of the Inclisiran Doses
Time Frame: From index date until the end of follow-up, assessed up to 48 months
|
Index date is the date of first use of the treatment.
|
From index date until the end of follow-up, assessed up to 48 months
|
|
Time Between Inclisiran Doses
Time Frame: From index date until the end of follow-up, assessed up to 48 months
|
Index date is the date of first use of the treatment.
|
From index date until the end of follow-up, assessed up to 48 months
|
|
Number of Anti-PCSK9-mAb Prescriptions
Time Frame: From index date until the end of follow-up, assessed up to 48 months
|
Index date is the date of first use of the treatment.
|
From index date until the end of follow-up, assessed up to 48 months
|
|
Time Between Anti-PCSK9-mAb Prescriptions
Time Frame: From index date until the end of follow-up, assessed up to 48 months
|
Index date is the date of first use of the treatment.
|
From index date until the end of follow-up, assessed up to 48 months
|
|
Association Between Treatment Adherence and Baseline Characteristics per Cohort
Time Frame: Baseline, up to 48 months
|
Multivariable regression models will be used to examine how baseline characteristics could be associated with treatment adherence per cohort.
Baseline characteristics may include age, sex, diagnosis, cardiovascular events, comorbidities, adherence to LLTs, and number of medications received at index and post-index.
|
Baseline, up to 48 months
|
|
Association Between Treatment Persistence and Baseline Characteristics per Cohort
Time Frame: Baseline, up to 48 months
|
Cox proportional hazards models will be used to examine how baseline characteristics could be associated with treatment persistence per cohort.
Baseline characteristics may include age, sex, diagnosis, cardiovascular events, comorbidities, adherence to LLTs, and number of medications received at index and post-index.
|
Baseline, up to 48 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 2, 2026
Primary Completion (Estimated)
October 30, 2026
Study Completion (Estimated)
October 30, 2026
Study Registration Dates
First Submitted
April 14, 2026
First Submitted That Met QC Criteria
April 14, 2026
First Posted (Actual)
April 22, 2026
Study Record Updates
Last Update Posted (Actual)
July 15, 2026
Last Update Submitted That Met QC Criteria
July 14, 2026
Last Verified
July 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Vascular Diseases
- Metabolism, Inborn Errors
- Genetic Diseases, Inborn
- Metabolic Diseases
- Hyperlipidemias
- Dyslipidemias
- Lipid Metabolism Disorders
- Arteriosclerosis
- Arterial Occlusive Diseases
- Lipid Metabolism, Inborn Errors
- Hyperlipoproteinemias
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Nutritional and Metabolic Diseases
- Cardiovascular Diseases
- Hyperlipoproteinemia Type II
- Atherosclerosis
Other Study ID Numbers
- CKJX839A12404
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.